Mektovi (binimetinib)

News alerts, weekly reports and conference planners

Company:

Medison, Ono Pharma, Pfizer, Pierre Fabre

Drug class:

MEK inhibitor

Related drugs:

BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
NRAS mutation	Melanoma	NRAS mutation	Melanoma	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
NRAS mutation	Cutaneous Melanoma	NRAS mutation	Cutaneous Melanoma	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2
SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	binimetinib + YD312 Sensitive: A2 - Guideline binimetinib + YD312 Sensitive : A2	binimetinib + YD312 Sensitive: A2 - Guideline binimetinib + YD312 Sensitive : A2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	binimetinib Sensitive: B - Late Trials binimetinib Sensitive : B	binimetinib Sensitive: B - Late Trials binimetinib Sensitive : B
BRAF V600E + BRAF V600K	Melanoma	BRAF V600E + BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B	binimetinib + encorafenib Sensitive: B - Late Trials binimetinib + encorafenib Sensitive : B
BRAF V600	Multiple Myeloma	BRAF V600	Multiple Myeloma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Ovarian Serous Adenocarcinoma	BRAF V600E	Ovarian Serous Adenocarcinoma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Pancreatic Cancer	BRAF V600E	Pancreatic Cancer	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600K	Solid Tumor	BRAF V600K	Solid Tumor	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Glioma	BRAF V600E	Glioma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRAF mutation	Melanoma	BRAF mutation	Melanoma	binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria binimetinib + encorafenib Sensitive : C2	binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria binimetinib + encorafenib Sensitive : C2
BRAF V600	Melanoma	BRAF V600	Melanoma	nivolumab + ipilimumab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab + binimetinib + encorafenib Sensitive : C2	nivolumab + ipilimumab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria nivolumab + ipilimumab + binimetinib + encorafenib Sensitive : C2
BRAF V600	Melanoma	BRAF V600	Melanoma	binimetinib Sensitive: C2 – Inclusion Criteria binimetinib Sensitive : C2	binimetinib Sensitive: C2 – Inclusion Criteria binimetinib Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria palbociclib + binimetinib Sensitive : C2	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria palbociclib + binimetinib Sensitive : C2
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	cetuximab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria cetuximab + binimetinib + encorafenib Sensitive : C2	cetuximab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria cetuximab + binimetinib + encorafenib Sensitive : C2
BRAF V600	Melanoma	BRAF V600	Melanoma	pembrolizumab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria pembrolizumab + binimetinib + encorafenib Sensitive : C2	pembrolizumab + binimetinib + encorafenib Sensitive: C2 – Inclusion Criteria pembrolizumab + binimetinib + encorafenib Sensitive : C2
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	binimetinib Sensitive: C2 – Inclusion Criteria binimetinib Sensitive : C2	binimetinib Sensitive: C2 – Inclusion Criteria binimetinib Sensitive : C2
RAS mutation	Colorectal Cancer	RAS mutation	Colorectal Cancer	binimetinib Sensitive: C2 – Inclusion Criteria binimetinib Sensitive : C2	binimetinib Sensitive: C2 – Inclusion Criteria binimetinib Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	binimetinib + ribociclib Sensitive: C3 – Early Trials binimetinib + ribociclib Sensitive : C3	binimetinib + ribociclib Sensitive: C3 – Early Trials binimetinib + ribociclib Sensitive : C3
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3

Mektovi (binimetinib)

Associations
(68)

Associations
(68)

Mektovi (binimetinib)

Associations(68)

Associations(68)

Associations
(68)

Associations
(68)